SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial. - Mena Lora AJ; Enders K; Wu H; Parra-Rodriguez L; Palma C; Saliba K; Laverdurre S; Smith PB; Anstrom KJ; Bozzette SA; Powderly WG (Therapeutic advances in infectious disease, 2025)